XOMA Corporation (XOMAP) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 4, 2026, XOMA Corporation (XOMAP) trades at a price-to-earnings ratio of -15.8x, with a stock price of $26.06 and trailing twelve-month earnings per share of $1.20.
The current P/E is 158% below its 5-year average of 27.3x. Over the past five years, XOMAP's P/E has ranged from a low of 12.6x to a high of 89.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.3x, XOMAP trades at a 168% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.3x.
Relative to the broader market, XOMAP trades at a notable discount to the S&P 500 median P/E of 26.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XOMAP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Royalty and IP Monetization Vehicles peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 26.6 | - | -7% | |
| $2B | 6.7Lowest | 0.65Best | +817%Best | |
| $765M | 38.6 | - | -83% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $26.47 | $2.10 | 12.6x | -54% | |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $25.84 | $0.29 | 89.1x | +226% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $24.32 | $1.66 | 14.7x | -46% |
| FY2022 Q2 | $25.40 | $1.62 | 15.7x | -43% | |
| FY2022 Q1 | $26.34 | $1.82 | 14.5x | -47% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $26.30 | $1.39 | 18.9x | -31% |
| FY2021 Q3 | $26.48 | $0.76 | 34.8x | +28% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $26.55 | $1.05 | 25.2x | -8% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $25.00 | $0.94 | 26.5x | -3% |
| FY2020 Q4 | $24.99 | $1.17 | 21.3x | -22% |
Average P/E for displayed period: 27.3x
See XOMAP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XOMAP Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare XOMAP vs AGIO
See how XOMAP stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is XOMAP stock overvalued or undervalued?
XOMAP trades at -15.8x P/E, below its 5-year average of 27.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does XOMAP's valuation compare to peers?
XOMA Corporation P/E of -15.8x compares to sector median of 23.3x. The discount suggests lower growth expectations or higher risk.
What is XOMAP's PEG ratio?
XOMAP PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2025.